Previse’s Epigenetic Test: A Game-Changer in Detecting Cancer Risk in Barrett’s Esophagus Patients

Previse’s Epigenetic Test: A Game-Changer in Detecting Cancer Risk in Barrett’s Esophagus Patients Previse, a leading gastrointestinal health company, has recently unveiled groundbreaking data on their flagship esopredict test, which demonstrates an unprecedented ability to predict the progression of Barrett’s esophagus to high-grade dysplasia or esophageal adenocarcinoma. This revelation comes from a clinical validation study […]